NexImmune, Inc. (OTCPK: NEXI)
Health Care · Biotechnology · US
$0.00
— today · +9900.0% 1Y
NexImmune, Inc. (OTCPK: NEXI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $139.00 and employs 6 people.
Over the last twelve months the share price has gained 9900.0%, trading between 0.00 and 2.17.
Tweenvest scores NexImmune, Inc. across four factors: quality 24/100. Its strongest factor is quality.
NEXI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $139.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -17.39
- Dividend yield
- —
- Beta (5Y)
- 4.28
- 52-week high
- $2.17
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.39M
- Employees
- 6
- Next earnings
- —
About NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
- Founded
- 2011
- Listed since
- Feb 12, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.60 | +0.62% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.00 | +0.15% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.98 | +0.59% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €875.60 | -2.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.84 | -0.85% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.